Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Regeneron shares poised for rebound: Barron's

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/07/2017 | 07:19pm CEST

Shares of Regeneron Pharmaceuticals Inc, which tumbled 32 percent in 2016, are poised for a rebound, the financial newspaper Barron's said.

A better-than-expected launch of Regeneron's skin treatment Dupixent caused shares to soar last week, the paper reported in its May 8 edition. If Dupixent usage grows faster than expected, it could take pressure off Regeneron's other drugs, including eye drug Eylea, Barron's said.

Regeneron said that 900 prescriptions had been written for Dupixent and that the number of doctors prescribing the drug had jumped by nearly 50 percent.

(Reporting by Olivia Oran; Editing by Phil Berlowitz)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
07/20 REGENERON PHARMACEUTICALS INC. : Details Findings in Breast Cancer [Preclinical ..
07/20 REGENERON PHARMACEUTICALS : Announces the 2017 Winners of the Prize for Creative..
07/13 REGENERON PHARMACEUTICALS : Reports Outline Immunoglobulins Findings from Regene..
07/13 REGENERON PHARMACEUTICALS : to Report Second Quarter 2017 Financial and Operatin..
07/13 REGENERON PHARMACEUTICALS : Announces the 2017 Winners of the Prize for Creative..
06/29 REGENERON PHARMACEUTICALS : Researchers from Regeneron Pharmaceuticals Inc. Repo..
06/29 REGENERON PHARMACEUTICALS : New Epilepsy Study Findings Have Been Reported by Re..
06/29 VEEVA : Standardizing on Veeva Vault Enhances Regeneron's Clinical and Regulator..
06/29 REGENERON PHARMACEUTICALS : Corporate News Blog - Regeneron and Sanofi Announced..
06/27 REGENERON PHARMACEUTICALS : ($REGN) Dips as Biotech Stocks Rebound
More news
News from SeekingAlpha
07/20 Cypress Semiconductor Will Go To $17 - Cramer's Lightning Round (7/19/17)
07/19 FDA's Flashing Green Light Boosts Novel Drug Approvals
07/13 CYTRX : SCLC Study Still Breathing?
07/10 Strong Small Cap Performance Drives Second-Quarter Gains
07/07 NICK'S PICKS 2017 : Halftime Report
Financials ($)
Sales 2017 5 495 M
EBIT 2017 2 190 M
Net income 2017 1 016 M
Finance 2017 2 105 M
Yield 2017 -
P/E ratio 2017 59,15
P/E ratio 2018 46,31
EV / Sales 2017 9,70x
EV / Sales 2018 8,57x
Capitalization 55 391 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 477 $
Spread / Average Target -8,5%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS40.54%55 391
AMGEN23.25%131 872
CELGENE CORPORATION19.00%106 434
GILEAD SCIENCES3.00%95 940
VERTEX PHARMACEUTICALS121.49%39 684
ACTELION20.63%30 398